Holen Sie sich die Stockscreener-App
6.91
0.00%
0.00
Handel nachbörslich:
6.96
0.05
+0.72%
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Institutional Investors Lost 4.6% Over the Past Week but Have Profited From Longer-term Gains - 富途牛牛
How Xeris’ Diversified Product Portfolio and XP-8121 Progress Could Shape Xeris Biopharma (XERS) Investors - Sahm
Xeris Biopharma (NASDAQ:XERS) and Metagenomi (NASDAQ:MGX) Critical Comparison - Defense World
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity (XERS) - Seeking Alpha
Y Intercept Hong Kong Ltd Lowers Holdings in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 Shares - MarketBeat
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unlocking a 53.91% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Market Trends: What is the implied volatility of Xeris Biopharma Holdings IncTrade Entry Report & Smart Swing Trading Alerts - baoquankhu1.vn
Buy Signal: Can RNST keep up with sector leadersJuly 2025 Market Mood & Growth Focused Entry Reports - baoquankhu1.vn
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Exploring a 46% Potential Upside for Investors - DirectorsTalk Interviews
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Updated 2025 Revenue Outlook - Sahm
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unveiling a 50% Potential Upside in Biotech - DirectorsTalk Interviews
Does Xeris Biopharma (XERS) Boosted 2025 Revenue Guidance Strengthen Its Commercial Momentum Narrative? - simplywall.st
How Investors Are Reacting To Xeris Biopharma (XERS) Raising 2025 Revenue Outlook And Recorlev Momentum - Sahm
Technical Analysis: What are Xeris Biopharma Holdings Incs technical support levels2025 Price Momentum & Smart Investment Allocation Insights - baoquankhu1.vn
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? - Yahoo Finance
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns - Yahoo Finance
Is Xeris Biopharma Holdings (XERS) Price Rally Still Justified After Recent Company Updates - Sahm
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents - Yahoo Finance
XERS: HC Wainwright & Co. Reiterates Buy Rating with $10.00 Pric - GuruFocus
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 15,000 Shares of Stock - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright - MarketBeat
Published on: 2026-01-13 01:49:04 - ulpravda.ru
Xeris Biopharma (XERS) Exceeds 2025 Revenue Expectations - GuruFocus
Will Xeris Biopharma Holdings Inc. stock outperform tech sector in 20252025 EndofYear Setup & Weekly High Potential Stock Alerts - Улправда
Breakout Move: Is Xeris Biopharma Holdings Inc. stock a smart buy before Fed meetingJuly 2025 Trade Ideas & AI Driven Price Predictions - Улправда
How Xeris Biopharma Holdings Inc. stock benefits from strong dollarJuly 2025 Update & AI Powered Buy and Sell Recommendations - Улправда
Is Xeris Biopharma Holdings Inc. stock positioned well for digital economyBreakout Watch & Smart Allocation Stock Reports - Улправда
Xeris Biopharma expects full-year 2025 revenue above estimates - MSN
Xeris Biopharma (NASDAQ:XERS) Shares Gap UpHere's Why - MarketBeat
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue - BioSpace
Xeris Biopharma Holdings, Inc. Updates Earnings Guidance for the Full-Year 2025 - marketscreener.com
A biotech treating 700 patients is on track for a record revenue year - Stock Titan
Xeris Biopharma director Shannon sells $176k in shares By Investing.com - Investing.com UK
Xeris Biopharma director Shannon sells $176k in shares - Investing.com
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Diversified Trust Co - MarketBeat
This Small Biotech Stock Is Still a Buy After Massive Bottom-Line Gift - TheStreet Pro
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Xeris Biopharma (NASDAQ:XERS) Trading Down 6.8%Time to Sell? - MarketBeat
Calamos Advisors LLC Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday - Finviz
Is Xeris Biopharma on the Verge of a Breakthrough? - StocksToTrade
Xeris Biopharma Holdings Inc. (XERS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
XERS FinancialsIncome Statement - Quiver Quantitative
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):